Compact Oxygen Generation Medical Devices: Compact Oxygen Generation, Medical (COGM) and Compact Oxygen Generation, Medical – At Altitude (COGM-A)

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DEFENSE HEALTH AGENCY

Contract Value

Not provided

Codes & Classification
Solicitation Number

HT9427-26-R-E001

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

AN13

Additional Details
Set Aside

NONE

Place of Performance

Maryland, UNITED STATES

SourceSAM
The Defense Health Agency (DHA), through its Contracting Activity (DHACA), has issued a solicitation for prototype proposals under the authority of 10 U.S.C. 4022, specifically utilizing the prototype Other Transaction Authority (pOTA). This procurement, identified by HT9427-26-R-E001, seeks innovative solutions for Compact Oxygen Generation Medical Devices, encompassing both standard Compact Oxygen Generation, Medical (COGM) units and Compact Oxygen Generation, Medical – At Altitude (COGM-A) variants. The initiative is managed by the Warfighter Expeditionary Medicine and Treatment Project Management Office (WEMT PMO) within the DHA Operational Medical Systems (OPMED) Project Management Office, based at Fort Detrick in Frederick, Maryland. The primary objective of this solicitation is to advance the development of medical oxygen generation technologies that are compact, reliable, and suitable for operational environments, including those encountered at altitude. These devices are intended to enhance the medical support capabilities available to military personnel in expeditionary and austere settings, directly supporting the health and readiness of the warfighter. The expected outcomes include the delivery of prototype devices that meet stringent performance, reliability, and operational requirements as detailed in the Request for Prototype Proposal (RPP) and its associated attachments. Key requirements for this procurement include the design, development, and demonstration of compact medical oxygen generation systems capable of functioning effectively in both standard and high-altitude conditions. Offerors are expected to address technical specifications, operational usability, and compliance with relevant medical and military standards. The RPP and its amendments provide comprehensive guidance on eligibility, preliminary screening, warranties, and representations, ensuring alignment with DHA’s operational and technical objectives. This opportunity is classified under NAICS code 541714, “Research and Development in Biotechnology (except Nanobiotechnology),” reflecting the emphasis on advanced biomedical research and prototype development. The Product Service Code is AN13. There are no set-aside restrictions associated with this solicitation, making it open to all qualified entities capable of meeting the outlined requirements. The place of performance for this effort is Maryland, United States, with project oversight and management centralized at Fort Detrick. The contracting entity is the Defense Health Agency, a federal office under the Department of Defense, ensuring that the project aligns with broader defense health and readiness priorities. Interested parties should note that the solicitation has been amended (Amendment 0001, dated March 3, 2026) to extend the proposal due date to March 11, 2026, and to clarify certain eligibility and warranty definitions. No further questions or phone calls regarding the RPP will be accepted. All relevant documentation, including the RPP, amendments, and responses to potential offeror questions, are available via the SAM.gov opportunity listing. For further information or to submit proposals, contractors may contact the primary point of contact, Shannon Lertora ([email protected]), or the secondary contact, Timothy Kelly ([email protected]). This solicitation represents a significant opportunity for organizations specializing in medical device innovation, biotechnology research, and military health solutions to contribute to the next generation of deployable medical oxygen generation capabilities for the Department of Defense.
Documents16